Reshape Lifesciences Inc (OTCMKTS:RSLS) Major Shareholder Armistice Capital Master Fund Acquires 396,072 Shares

Reshape Lifesciences Inc (OTCMKTS:RSLS) major shareholder Armistice Capital Master Fund acquired 396,072 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average price of $0.05 per share, with a total value of $19,803.60. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Armistice Capital Master Fund also recently made the following trade(s):

  • On Thursday, August 29th, Armistice Capital Master Fund bought 200,000 shares of Reshape Lifesciences stock. The shares were bought at an average price of $0.07 per share, with a total value of $14,000.00.
  • On Thursday, August 8th, Armistice Capital Master Fund purchased 350,000 shares of Reshape Lifesciences stock. The shares were acquired at an average cost of $0.07 per share, for a total transaction of $24,500.00.
  • On Friday, July 26th, Armistice Capital Master Fund purchased 500,000 shares of Reshape Lifesciences stock. The shares were acquired at an average cost of $0.08 per share, for a total transaction of $40,000.00.

Shares of OTCMKTS RSLS opened at $0.06 on Friday. The company has a quick ratio of 0.93, a current ratio of 1.04 and a debt-to-equity ratio of 0.05. Reshape Lifesciences Inc has a 52 week low of $0.04 and a 52 week high of $8.40. The firm’s fifty day moving average is $0.11 and its 200 day moving average is $0.12.

Reshape Lifesciences (OTCMKTS:RSLS) last issued its quarterly earnings data on Wednesday, August 14th. The medical device company reported ($0.84) earnings per share (EPS) for the quarter. Reshape Lifesciences had a negative net margin of 689.90% and a negative return on equity of 86.52%. The company had revenue of $4.45 million for the quarter.

About Reshape Lifesciences

ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.

Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Insider Buying and Selling by Quarter for Reshape Lifesciences (OTCMKTS:RSLS)

Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply